Never forget why we started, never stop where we pursue

Allist pockets awards of “Drug Innovator in the Ascendant” and “Drug Innovation Leader”

As the biopharmaceutical industry in China enters a time of transformation, “innovation” has become the keyword. The 1st Drug Innovation Jishi Award Summit & Award Ceremony hosted by Securities Times, a leading media outlet in the field of finance and economics in China, successfully concluded on June 10. After expert evaluation and online voting, Shanghai Allist Pharmaceuticals Co., Ltd. (Allist) and its Chairman, Mr. Du Jinhao, were respectively awarded as “Top 10 Drug Innovator in the Ascendant 2020” and “Top 10 Drug Innovation Leader 2020”.


Chairman Du, upon his attendance at the Summit at the invitation of the host organization, co-founded the “China Drug Innovation Leaders Club” and delivered a speech on behalf of the Club, in which he said, “This platform provided by Securities Times will bring together Chinese pharmaceutical companies, especially drug innovators, for joint efforts in promoting the development of this promising industry in our country and exploring our way toward the international market amid new changes. We will, with no spared endeavor, work together to break a path for China to evolve from a big drug producer to a competitive drug innovator.”

Founded by Chairman Du in Shanghai in 2004, Allist is an innovative drug company dedicated to cancer treatment. Since its establishment, carrying the mission of “Advancing Long Life with Innovation of Science and Technology”, it seeks to cater to the unmet clinical demands in the global pharmaceutical market and is dedicated to research and development of first-in-class and best-in-class medicines. Allist has built a comprehensive system for the R&D of new drugs that are designed to work on targets that have been scientifically proved, a system that covers all links including discovery and optimization of lead compounds, evaluation and identification of candidate drugs, preclinical and clinical studies, as well as new drug registration, scale production and commercialization.

Since 2004, Allist has successfully developed two National Category-I innovative drugs, and led or participated in three of China’s key national technology projects for drug innovation, one National High-tech R&D Program (863 Program) and a total of 6 provincial- and city-level technological projects. On March 3, 2021, Allist’s first Category-I innovative drug for cancer treatment — Furmonertinib was approved of for marketing in China. Furmonertinib targets adult patients who used to experience progression of disease amid or after treatments with EGFR-TKI and diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). It is expected to serve as a new choice for standard treatment of NSCLC. Allist will remain committed to the field of cancer treatment, stepping up its efforts on an array of different types of cancers and keeping expanding the products in research, in order to establish strategic and advantageous pipelines.

Ever since its beginning, Allist has been poised as a Chinese innovative drug maker that embodies the combination of entrepreneurship and scientist ethos. Independent innovation has been the unremitting commitment of its founder, Mr. Du Jinhao. It was exactly this dedication to innovation that helped Allist weather through the ups and downs in its early years; and Mr. Du, with his acute insights and strategic thinking based on his years of business management experience, locked his forward-looking eyes and Allist’s future on the area of cancer treatment, and led Allist to finish this important strategic transformation. He put on doctor’s gown and walked in the labs where he joined R&D team to check data processing and work on solutions. These endeavors pushed Allist forward in its transformation from a R&D startup to a leading developer, producer and seller of innovative drugs in China, gaining it the recognition of the capital market. In 2019, Allist successfully finished the A and A+ rounds of financing, and finally in December 2020 it was listed in the STAR market via the Shanghai Stock Exchange.

Chairman Du said firmly, “Innovation can prosper a country and its people; innovation is also the fundamental driving force behind the advancement of a company. Each and every effort of Allist on the road of innovation is oriented toward all the unmet medical needs of patients. With the three engines of core products, products in development and imported products, we remain committed to continuously providing effective and inclusive innovative drugs for patients in China, or even, around the world.”